Acurx Pharmaceuticals Ibezapolstat Phase 2b Clinical Trial Success
Drug Updates

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced positive comparative microbiology and microbiome data for ibezapolstat, its lead antibiotic candidate, from the Company’s recently completed Phase 2b clinical trial in patients with CDI.  Data showed that ibezapolstat outperformed vancomycin, a standard […]

Drug Updates

Anatara’s IBS-D clinical trial to leverage Microba Life Sciences’ precision microbiome analysis

Precision microbiome science company, Microba Life Sciences, will work with Anatara Life Sciences (ASX:ANR) to complete microbiome analysis for a much-needed therapeutic treatment for sufferers of IBS-D. Anatara have commenced recruitment for a phase 1/2 clinical trial of their Gastrointestinal Re-Programming complementary medicine (GaRP) to address an unmet clinical need for IBS-D.   Microba will apply […]